MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.
| Revenue (Most Recent Fiscal Year) | $38.63M |
| Net Income (Most Recent Fiscal Year) | $-41.06M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.17 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.78 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -125.22% |
| Net Margin (Trailing 12 Months) | -125.22% |
| Return on Equity (Trailing 12 Months) | -22.12% |
| Return on Assets (Trailing 12 Months) | -19.10% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.40 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.81 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.79 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.39 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.43 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 106.61M |
| Free Float | 103.09M |
| Market Capitalization | $149.25M |
| Average Volume (Last 20 Days) | 1.22M |
| Beta (Past 60 Months) | 1.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 68.81% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |